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Objectives. Myositis-specific autoantibodies (MSAs) are useful tools in identifying 
clinically homogenous subsets and predicting prognosis of patients with idiopathic 
inflammatory myopathies (IIM) including polymyositis (PM) and dermatomyositis 
(DM). Recent studies have revealed that anti-NXP2 antibody (Ab) is a major MSA in 
juvenile dermatomyositis (JDM). In this study, we evaluated the frequencies and clinical 
associations of anti-NXP2 Ab in adult IIM patients. 
Methods. Clinical data and sera were collected from 507 adult Japanese patients with 
IIM (445 adult DM, and 62 adult PM). As disease controls, 11 with JDM, 108 with 
systemic lupus erythematosus, 433 with systemic sclerosis, and 124 with idiopathic 
pulmonary fibrosis were assessed. Sera were examined for anti-NXP2 Ab by 
immunoprecipitation and Western blotting using polyclonal anti-NXP2 Ab. 
Results. Seven patients (1.6%) with adult DM and 1 (1.6%) with adult PM were 
positive for anti-NXP2 Ab. Except for 2 patients with JDM, no patients as disease 
controls were positive for this autoAb. Among 8 adult IIM patients, 3 had internal 
malignancies within 3 years of diagnosis of IIM. Another DM patient also had a 
metastatic cancer at the diagnosis. All of the carcinomas were advanced stage (stage 
IIIb-IV). 
Conclusions. While less common than in juvenile IIM, anti-NXP2 Ab was found in 
adult IIM. Anti-NXP2 Ab may be associated with adult IIM with malignancy. 
 




Idiopathic inflammatory myopathies (IIM), including polymyositis (PM) and 
dermatomyositis (DM), are characterized by chronic inflammation of skeletal muscles 
and/or skin eruptions [1]. Although the etiology remains unclear, they are considered as 
autoimmune diseases. The presence of disease-specific autoantibodies (autoAbs), 
known as myositis-specific autoAbs (MSAs), is a prominent feature. Moreover, MSAs 
are strongly associated with distinct clinical phenotypes and thus classify patients into 
groups with more homogenous clinical features [2-4]. These MSAs include antibodies 
(Abs) to aminoacyl-tRNA synthetases (ARS), the Mi-2 protein, the signal-recognition 
particle (SRP), transcriptional intermediary factor-1 (TIF1; anti-155/140 Ab) [5-7], and 
melanoma differentiation-associated gene-5 (MDA5; anti-CADM140 Ab) [8].  
Oddis and colleagues first described anti-MJ Ab in a US cohort of juvenile DM 
(JDM) [9], and Targoff et al. subsequently identified that the antigen of anti-MJ Ab is 
nuclear matrix protein NXP2 (MORC3) [10]. Gunawardena et al. and Espada et al. have 
demonstrated that anti-NXP2 Ab is among the most common MSAs in JDM [11, 12]. In 
this study, we evaluated the frequencies and clinical associations of anti-NXP2 Ab in 
adult IIM patients. 
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PATIENTS AND METHODS 
Patients 
Serum samples were obtained from 507 consecutive Japanese adult patients with IIM, 
445 with DM and 62 with PM, who had been followed up in the Department of 
Dermatology, Kanazawa University Hospital and collaborating medical centers from 
2003 to 2010. All PM patients and 365 DM patients fulfilled Bohan and Peter’s criteria 
[13, 14]. The remaining 80 did not, but fulfilled Sontheimer’s criteria of clinically 
amyopathic DM (CADM) [15]. Among DM patients, As disease controls, 11 with JDM. 
108 with systemic lupus erythematosus, 433 with systemic sclerosis, and 124 with 
idiopathic pulmonary fibrosis were assessed. Clinical information was collected 
retrospectively by reviewing their clinical medical charts. The protocol was approved by 
Kanazawa University Graduate School of Medical Science. 
 
Immunoprecipitation and Western blotting 
Ten microliters of serum was incubated with 2 mg of protein A-Sepharose beads 
(Amersham Biosciences, Piscataway, NJ, USA) in immunoprecipitation buffer (10 mM 
Tris-HCl, pH 8.0, 50 mM NaCl, 0.1% Nonidet P-40) for 2 hours. Beads were then 
mixed with 35S-labeled or unlabeled K562 cell extracts derived from 107 cells and 
rotated at 4℃ for 2 hours. After five washes, precipitated proteins were fractionated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by autoradiography or 
Western blotting. 
For Western blotting, proteins were transferred onto a nitrocellulose membrane. 
After blocking, the membrane was incubated with mouse polyclonal anti-human NXP2 
Ab (Abcam, Cambridge, UK), and then with horseradish peroxidase-conjugated goat 
anti-mouse IgG Ab (Thermo Scientific, Rockford, IL, USA). The membrane was 




Fisher’s exact probability tests were used for comparison of frequencies. Bonferroni’s 
test was examined for multiple comparisons of values following normal distribution. 
The values that were not normally distributed were evaluated by Mann-Whitney U test. 




Detection of anti-NXP2 Abs 
Sera from 507 adult Japanese IIM patients were screened for anti-NXP2 Ab. From 
K562 cell extracts, 8 sera precipitated a 140-kDa protein, which was different from 
other known autoantigens (Figure 1A). Additionally, 2 JDM patients were positive for 
this 140-kDa protein. No sera from other diseases precipitated this 140-kDa protein. On 
SDS-PAGE, the 140-kDa band was slightly higher than the 140-kDa band of anti-TIF1 
Ab, and was not accompanied by a 155-kDa band (Figure 1A). While this 140-kDa 
protein migrated closely to MDA5, these sera were negative for anti-MDA5 Ab by an 
enzyme-linked immunosorbent assay using recombinant MDA5 protein as antigen (data 
not shown). These sera were confirmed to react with NXP2 since precipitated proteins 
were recognized by polyclonal Abs to NXP2 in Western blotting (Figure 1B). They also 
reacted with recombinant human NXP2 protein by Western blotting (online 
supplementary Figure S1). These sera were negative for other MSAs, and did not have 
other known autoAbs, except for patient B, who was positive for anti-SS-A/Ro and 
SS-B/La Abs. In indirect immunofluorescence, 5 showed negative staining, while 3 
stained nuclei in speckled pattern at the maximum dilution of x80.  
 
Clinical and laboratory profiles of IIM patients with anti-NXP2 Abs 
Among 507 adult IIM patients, 8 patients were positive for anti-NXP2 Ab: 7 (1.6%) in 
445 adult DM patients and 1 (1.6%) in 62 adult PM patients. All patients with 
anti-NXP2 Ab showed strong muscle weakness and high elevation of serum CK levels. 
Remarkably, internal malignancies found within 3 years of the diagnosis of IIM were 
present in 37.5% (3/8) (Table 2). All these patients had advanced disease (satage 
IIIb-IV). Additionally, in a patient (C), prostate cancer was found 42 months before, and 
it was metastatic when the diagnosis of DM was made. However, he was excluded from 
the statistical analysis since he did not meet the above criteria. ILD was not found. 
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During the follow-up period varying from 2 to 61 months, 7 of 8 patients, 
except for patient H, were treated with systemic corticosteroid therapy. Patient A also 
received methotrexate, and patient D also underwent intravenous Ig therapy. While the 
response to the treatment was favorable in all patients, 2 (C and G) died of malignancy.  
 
Comparison with other MSAs 
In addition to 7 patients positive for anti-NXP2 Ab, adult DM patients in this study 
included 74 patients with anti-TIF1 Ab and 15 patients with anti-Mi-2 Ab. They also 
included 51 with anti-MDA5 Ab, 26 with anti-PL-7 Ab, 18 with anti-Jo-1 Ab, and 8 
with anti-PL-12 Ab. Among them, since anti-TIF1 Ab and anti-Mi-2 Ab are specifically 
associated with DM, the clinical features of patients with anti-NXP2 Ab were compared 
with those with anti-TIF1 Ab and anti-Mi-2 Ab (Table 2).  
Anti-NXP2 Ab was predominantly found in male patients. Although Gottron’s 
sign was slightly less frequent, there was no significant difference for the frequency of 
each cutaneous manifestation. The frequency of fever was significant higher than that in 
anti-TIF1-positive DM patients. The highest CK level was similar to that of anti-Mi-2 
Ab-positive DM, and significant higher than that of anti-TIF1 Ab. The frequency of 
internal malignancy in those with anti-NXP2 Ab was lower than that in anti-TIF1 Ab, 




Recently, two studies demonstrated that anti-NXP2 Ab was detected in 23% and 25% of 
JDM patients in UK and Argentina, respectively [11, 12]. While the number of patients 
was small, anti-NXP2 Ab was detected in 18% in the control JDM population in this 
study. Therefore, anti-NXP2 Ab is likely to be a major MSA in JDM across racial 
groups as well as anti-TIF1 Ab, which is detected at 23-29% in JDM [16]. In addition to 
JDM, Espada et al. reported that 2 (28%) of 7 patients with juvenile PM were also 
positive for anti-NXP2 Ab [12]. In this study, we identified 8 anti-NXP2 Ab-positive 
adult patients in a Japanese cohort of IIM. The frequencies were 1.6% in both adult DM 
and adult PM. Therefore, while the population sizes of DM and PM are substantially 
different, anti-NXP2 Ab has been found at similar frequencies both in juvenile and adult 
IIM [12]. By contrast, in a UK cohort, Betteridge et al. preliminarily reported that 
anti-NXP2 Ab was detected in 13 (5%) DM patients but not in PM patients [17]. 
Intriguingly, 37.5% of adult IIM patients positive for anti-NXP2 Ab had 
malignancy which was found within 3 years in addition to a patient with metastatic 
prostate cancer found 42 months before. Moreover, all of these carcinomas were at an 
advanced stage. Anti-TIF1 Ab also has a strong association with internal malignancy in 
adult DM, as it is found in 50-70% of cancer-associated DM patients [5, 6, 18]. 
Therefore, while anti-NXP2 Ab may not be restricted to DM, anti-TIF1 Ab and 
anti-NXP2 Ab may have a shared property in that they represent two clinical subsets of 
cancer-associated adult DM and JDM. However, in contrast to our study, Betteridge et 
al. reported that anti-NXP2 Ab was not associated with malignancy but with interstitial 
lung disease [17]. This may be due to ethnical differences. It may have also resulted 
from different distribution of patients between Dermatology and Rheumatology clinics. 
Since both studies had relatively small numbers of patients, more studies are needed to 
evaluate more precise clinical relevance of anti-NXP2 Ab in IIM patients. 
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Among adult DM patients, anti-NXP2 Ab appeared to have strong muscle 
involvement, while we could not find any particular cutaneous manifestations related to 
anti-NXP2 Ab. Unlike anti-NXP2-positive JDM [11], no adult DM patients with 
anti-NXP2 Ab exhibited cutaneous calcinosis. This may be due to the relatively low 
incidence of calcinosis in adult DM compared with that in JDM. 
In summary, this study described that anti-NXP2 Ab was found in adult IIM 
patients, and suggesting a possibility that anti-NXP2 Ab is correlated with 
cancer-associated myositis. NXP2 is involved in the activation and localization of a 
tumor suppressor gene, p53 [19]. TIF1 proteins also have functional relationship with 
p53 [20]. Since these two autoAbs may share similar clinical characteristics, especially 
the association with cancer, they may develop during anti-tumor immune responses.  
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Table 1. Clinical and laboratory profile of adult patients with dermatomyositis (DM) or polymyositis (PM) positive for anti-NXP2 Ab* 
 
Patient A B C D E F G H 
Age (years) 23 34 54 57 57 61 62 68 
Sex male female male male male male female male 
Diagnosis DM DM DM DM DM DM PM DM 
Duration (mo) 11 21 10 8 23 4 2 7 
Heliotrope rash - + + + + - - + 
Gottron's sign + - + + - - - + 
Perionychia erythema - - + + + + - - 
Nailfold punctuated hemorrhage - - + - + + - + 
V sign - - + + + - - - 
Shawl sign - - + + + - - - 
Scratch dermatitis - + - + - + - - 
erythema of extensor extremities - + + + + + - - 
Calcinosis - - - - - - - - 
Blistering - - - - - - - - 
Ulceration - - - - + - - - 
Muscle weakness + + + + + + + + 
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Raynaud’s phenomenon - - - - - - - - 
Fever - - + - + + + + 
Arthralgia - + - - - - - - 
Elevation of CK + + + + + + + + 
Highest CK level (IU/l) 3857 1877 4927 1539 17140 26685 3713 3722 
IIF titer <40 80 <40 40 <40 <40 80 <40 
IIF staining pattern - Sp - Sp - - Sp - 
ILD - - - - - - - - 
Malignancy - - + + - - + + 
  Origin - - Prostate Pancreas - - Gallbladder Lung 
  Histology - - AC ND - - AC SCC 
  Stage - - IV IVb - - IVb IIIb 
  Period of diagnosis** - - 42 mo before 6 mo after - - Simultaneous 3 mo before 
 
*CADM, clinically amyopathic DM; mo, month; CK, creatine kinase; IIF, indirect immunofluorescence; Sp, speckled; ILD, interstitial lung disease; 
AC, adenocarcinoma; SSC, squamous cell carcinoma; ND, not done. ** Period of diagnosis indicates when the diagnosis of malignancy was made 
before or after the onset of IIM. 
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Table 2. Comparison of clinical and laboratory profile of adult dermatomyositis patients with anti-NXP2 Ab, anti-TIF1 Ab, and anti-Mi-2 Ab* 
 
    P-Values 
 anti-NXP2-positive anti-TIF1-positive anti-Mi-2-positive vs. anti-TIF1 vs. anti-Mi-2 
Number 7 74 15   
Age at onset, mean (range) 57 (23-68) 59 (27-89) 50 (16-67) N.S. N.S. 
Sex (male:female) 6:1 24: 34 8: 7 0.033 N.S. 
Skin eruptions      
 Heliotrope rash 71 62 60 N.S. N.S. 
 Gottron's sign 57 81 87 N.S. N.S. 
 Perionychia erythema 57 57 60 N.S. N.S. 
 Nailfold punctuated hemorrhage 57 40 73 N.S. N.S. 
 Trunk erythema 57 62 53 N.S. N.S. 
 Calcinosis 0 2 7 N.S. N.S. 
 Ulceration 14 7 0 N.S. N.S. 
Clinical features      
 Muscle weakness 100 69 93 N.S. N.S. 
 Raynaud phenomenon 0 9 0 N.S. N.S. 
 Arthritis 14 3 7 N.S. N.S. 
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 Fever 57 16 20 0.025 N.S. 
Organ involvement      
 Interstitial lung disease 0 13 13 N.S. N.S. 
 Internal malignancy within 3 years 29 66 7 N.S. N.S. 
Laboratory findings      
 Elevated CK, % 100 63 100 N.S. N.S. 
 Highest CK level, IU/l, mean (range) 3857 (1539-26685) 425 (40-8670) 3934 (401-10000) < 0.001 N.S. 
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Figure 1. Detection of anti-NXP2 Ab. A, Immunoprecipitant from 35S-labeled K562 
cell extract using serum samples were subjected to 7% SDS-PAGE. Lanes A-H 
correspond to anti-NXP2-positive patients shown in Table 1. As controls, the prototype 
sera positive for anti-TIF1 Ab and anti-MDA5 Ab and normal control serum were also 
examined. Molecular weights (MW) are shown on the left. The position of the 140-kDa 
NXP2 protein is indicated by an arrow. B, K562 cell extracts were immunoprecipitated 
with anti-NXP2-positive sera (patients A-H), anti-MDA5-positive sera, 
anti-TIF1-positive sera, or normal control sera, and were subjected to SDS-PAGE, 
electro-transferred onto nitrocellulose membranes, and probed with polyclonal 

































Anti-NXP2 sera? Control sera?
